FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W168228701> ?p ?o ?g. }

• W168228701 abstract "Abstract Introduction Management of B-cell chronic lymphocytic leukemia (CLL) is currently undergoing profound changes. Accordingly, new treatment options with an expected less toxicity than standard regimens are been explored. Recent results show that chemoimmunotherapy may improve the life expectancy of CLLpatients and has proven to be more efficient than chemotherapy alone in depleting malignant cells. Despite its efficacy, little is known about its precise immunomodulatory effects. Aim To evaluate the effects of chemoimmunotherapy with bendamustine plusrituximab (BR) on the distribution of normal residual leucocyte populations in peripheral blood (PB) from advanced-stage CLL patients, with special emphasis on maturation-associated B-cell subsets (immature, naïve, memory IgM/IgG/IgA and plasma cells). Material and Methods Distribution of PB neoplastic cells and residual normal immune cell subpopulations were analyzed in 72 CLL patients with advanced disease (Binet B/C), before therapy (M0) and after 1 course of BR (M1). The same analysis was repeated 3 months after completing treatment (M3) in 31/72 patients. PB leucocyte cell subsets were identified at each time-point by 8-color flow cytometry with monoclonal antibody reagents against CD3, CD4, CD5, CD8, TCRgd, CD19, CD20, CD27, CD38, CD45, CD56, sIgM, sIgA, sIgG, sIgLambda and sIgKappa. Results After the first BR course, absolute counts of all PB myeloid subsets were significantly decreased as compared to time M0, including neutrophils (2,744±1,830 vs 4,764±2,906 cells/uL, p<0.001), eosinophils (132±185 vs 215±245 cells/uL; p<0.001), basophils (37±28 vs 59±47 cells/uL, p<0.001), monocytes (334±280 vs 504±424 cells/uL, p=0.001) and dendritic cells (DCs, 41±40 vs 89±168 cells/uL, p=0.02), as well as NK cells (120±147 vs 550±599 cells/uL, p<0.001). At M3, all these populations remained decreased when compared to M0, but at similar levels to M1 (except for the absolute number of DCs, found to be increased vs. M1 -74±46 vs 41±40 cells/uL, p=0.008- and closer to M0). In turn, total T cells were reduced in M1 as compared to M0 values (818±655 vs 3,905±2,375 cells/uL, p<0.001), due to decreased numbers of CD4+ (424±376 vs 1,573±1,204 cells/uL, p<0.001), CD8+ (342±330 vs 1,334±1,218 cells/uL, p<0.001) and TCRgd (21±28 vs 141±289 cells/uL, p=0.001) T cells, leading to an increased CD4/CD8 ratio (1.8±1.3 vs 1.4±0.8, p=0.004). Also, decreased levels of CD4 (222±156 cells/uL), CD8 (501±544 cells/uL) and TCRgd (21±40 cells/uL) T cells were observed at time M3 vs. baseline values. No changes (p>0.05) were observed for CD8 and TCRgd for M3 vs. M1, while CD4+ T-cell numbers were significantly reduced (p=0.006), resulting in an inverted CD4/CD8 ratio (0.9±1.0 vs. 1.8±1.3, p=0.005) at the M3 time-point. As regards B cells, the absolute count of both neoplastic and normal B lymphocytes were significantly decreased at time M1 vs. M0 (3,363±9,353 vs 53,521±56,602 CLL cells/uL and 2±6 vs 58±107 normal B-cells/uL, p=0.006 and p<0.001, respectively). Within the normal residual B-cell compartment, we found significantly decreased numbers of immature (0.07±0.22 vs 6.55±21.64 cells/uL, p=0.01) and memory (1.3±14.7 vs 35.1±43.6 cells/uL, p<0.001) B cells -including sIgM (0.5±2.3 vs 14.5±24.8 cells/uL, p<0.001), sIgG (0.2±1.0 vs 11.5±17.2 cells/uL; p<0.001) and sIgA (0.6±3.1 vs 9.5±12.5 cells/uL, p<0.001) memory B cells-. At time M3, decreased (p<0.01) naïve (0.46±2.58 cells/uL) and memory B-cells (1.34±6.75 cells/uL), including IgM (0.46±2.58 cells/uL), IgG (0.34±1.69 cells/uL) and IgA (0.09±0.31 cells/uL), but not immature cells (2.28±8.84 cells/uL, p=0.9), were observed as compared to time M0. Differences did not reach statistical significance when comparing M3 vs. M1. The number of circulating plasma cells did not significantly vary during treatment. Conclusions All PB leucocyte subsets are affected by BR treatment in advanced-stage CLL. Interestingly, at time M3 the CD4+ T-cell subset continues to be decreased, while the other T-cell compartments seem to remain stable. Also, normal B cells are affected by BR treatment, and the depletion induced after one course therapy is maintained even three months after finishing BR therapy, except for immature B cells, that seem to be the first to recover in PB. Further studies will offer a more accurate insight into the biology of cell recovery during and after BR therapy in CLL patients. Disclosures: No relevant conflicts of interest to declare." @default.
• W168228701 created "2016-06-24" @default.
• W168228701 creator A5002880702 @default.
• W168228701 creator A5008703895 @default.
• W168228701 creator A5010151310 @default.
• W168228701 creator A5010521370 @default.
• W168228701 creator A5016855969 @default.
• W168228701 creator A5022378149 @default.
• W168228701 creator A5030136239 @default.
• W168228701 creator A5030925049 @default.
• W168228701 creator A5039277687 @default.
• W168228701 creator A5046102184 @default.
• W168228701 creator A5047279659 @default.
• W168228701 creator A5048766729 @default.
• W168228701 creator A5055430013 @default.
• W168228701 creator A5057247691 @default.
• W168228701 creator A5074229553 @default.
• W168228701 creator A5082366310 @default.
• W168228701 creator A5088409474 @default.
• W168228701 date "2013-11-15" @default.
• W168228701 modified "2023-10-05" @default.
• W168228701 title "Effects Of Bendamustine Plus Rituximab On The Distribution Of Normal Peripheral Blood Leucocyte Populations In Advanced-Stage Chronic Lymphocytic Leukemia (CLL)" @default.
• W168228701 doi "https://doi.org/10.1182/blood.v122.21.5289.5289" @default.
• W168228701 hasPublicationYear "2013" @default.
• W168228701 type Work @default.
• W168228701 sameAs 168228701 @default.
• W168228701 citedByCount "1" @default.
• W168228701 countsByYear W1682287012014 @default.
• W168228701 crossrefType "journal-article" @default.
• W168228701 hasAuthorship W168228701A5002880702 @default.
• W168228701 hasAuthorship W168228701A5008703895 @default.
• W168228701 hasAuthorship W168228701A5010151310 @default.
• W168228701 hasAuthorship W168228701A5010521370 @default.
• W168228701 hasAuthorship W168228701A5016855969 @default.
• W168228701 hasAuthorship W168228701A5022378149 @default.
• W168228701 hasAuthorship W168228701A5030136239 @default.
• W168228701 hasAuthorship W168228701A5030925049 @default.
• W168228701 hasAuthorship W168228701A5039277687 @default.
• W168228701 hasAuthorship W168228701A5046102184 @default.
• W168228701 hasAuthorship W168228701A5047279659 @default.
• W168228701 hasAuthorship W168228701A5048766729 @default.
• W168228701 hasAuthorship W168228701A5055430013 @default.
• W168228701 hasAuthorship W168228701A5057247691 @default.
• W168228701 hasAuthorship W168228701A5074229553 @default.
• W168228701 hasAuthorship W168228701A5082366310 @default.
• W168228701 hasAuthorship W168228701A5088409474 @default.
• W168228701 hasConcept C113067387 @default.
• W168228701 hasConcept C126322002 @default.
• W168228701 hasConcept C159654299 @default.
• W168228701 hasConcept C18031839 @default.
• W168228701 hasConcept C203014093 @default.
• W168228701 hasConcept C2777938653 @default.
• W168228701 hasConcept C2778461978 @default.
• W168228701 hasConcept C2780653079 @default.
• W168228701 hasConcept C2780790343 @default.
• W168228701 hasConcept C2781442060 @default.
• W168228701 hasConcept C71924100 @default.
• W168228701 hasConceptScore W168228701C113067387 @default.
• W168228701 hasConceptScore W168228701C126322002 @default.
• W168228701 hasConceptScore W168228701C159654299 @default.
• W168228701 hasConceptScore W168228701C18031839 @default.
• W168228701 hasConceptScore W168228701C203014093 @default.
• W168228701 hasConceptScore W168228701C2777938653 @default.
• W168228701 hasConceptScore W168228701C2778461978 @default.
• W168228701 hasConceptScore W168228701C2780653079 @default.
• W168228701 hasConceptScore W168228701C2780790343 @default.
• W168228701 hasConceptScore W168228701C2781442060 @default.
• W168228701 hasConceptScore W168228701C71924100 @default.
• W168228701 hasLocation W1682287011 @default.
• W168228701 hasOpenAccess W168228701 @default.
• W168228701 hasPrimaryLocation W1682287011 @default.
• W168228701 hasRelatedWork W122367818 @default.
• W168228701 hasRelatedWork W165456120 @default.
• W168228701 hasRelatedWork W2002671207 @default.
• W168228701 hasRelatedWork W2316550695 @default.
• W168228701 hasRelatedWork W2360816004 @default.
• W168228701 hasRelatedWork W2411314248 @default.
• W168228701 hasRelatedWork W2413893706 @default.
• W168228701 hasRelatedWork W2416980841 @default.
• W168228701 hasRelatedWork W2538028159 @default.
• W168228701 hasRelatedWork W2563385628 @default.
• W168228701 hasRelatedWork W2587045623 @default.
• W168228701 hasRelatedWork W2771061373 @default.
• W168228701 hasRelatedWork W2791772673 @default.
• W168228701 hasRelatedWork W2910963050 @default.
• W168228701 hasRelatedWork W2977084781 @default.
• W168228701 hasRelatedWork W2992574296 @default.
• W168228701 hasRelatedWork W2993975955 @default.
• W168228701 hasRelatedWork W3149047701 @default.
• W168228701 hasRelatedWork W3165146310 @default.
• W168228701 hasRelatedWork W2183178340 @default.
• W168228701 isParatext "false" @default.
• W168228701 isRetracted "false" @default.
• W168228701 magId "168228701" @default.
• W168228701 workType "article" @default.